Literature DB >> 28861323

POU2F1 promotes growth and metastasis of hepatocellular carcinoma through the FAT1 signaling pathway.

Hong Yan Zhu1, Guan Yi Cao1, Shi Ping Wang1, Yu Chen1, Guo Dong Liu1, Yu Jie Gao2, Jian Ping Hu1.   

Abstract

Increasing evidence suggests that POU domain class 2 transcription factor 1 (POU2F1) participates in carcinogenesis and cancer progression via promotion of cell proliferation and metastasis; however, the functional role of POU2F1 in hepatocellular carcinoma (HCC) is largely unknown. In this study, we determined that POU2F1 was significantly up-regulated in HCC tumor tissue and cell lines. We demonstrated that POU2F1 over-expression promoted HCC cell proliferation, colony formation, migration, and invasion, while silencing of POU2F1 inhibited these malignant phenotypes. In vivo experiments indicated that knockdown of POU2F1 inhibited HCC cell metastasis and xenograft growth, whereas ectopic expression of POU2F1 promoted these cellular functions. Microarray analysis suggests that FAT atypical cadherin 1 (FAT1) can function downstream of POU2F1. Functionally, we demonstrated that POU2F1 knockdown induced growth suppression and metastasis inhibition of HCC cells and inactivated the FAT1 pathway, indicating that POU2F1 is a potential novel therapeutic target in HCC.

Entities:  

Keywords:  FAT1; POU2F1; hepatocellular carcinoma; metastasis

Year:  2017        PMID: 28861323      PMCID: PMC5574939     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  18 in total

1.  ACK1 promotes gastric cancer epithelial-mesenchymal transition and metastasis through AKT-POU2F1-ECD signalling.

Authors:  Song-Hui Xu; Jin-Zhou Huang; Man-Li Xu; Guangchuang Yu; Xing-Feng Yin; De Chen; Guang-Rong Yan
Journal:  J Pathol       Date:  2015-03-09       Impact factor: 7.996

2.  The tumor suppressor FAT1 modulates WNT activity in multiple cancers.

Authors: 
Journal:  Cancer Discov       Date:  2013-02-07       Impact factor: 39.397

3.  Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Authors:  Elisa Wurmbach; Ying-bei Chen; Greg Khitrov; Weijia Zhang; Sasan Roayaie; Myron Schwartz; Isabel Fiel; Swan Thung; Vincenzo Mazzaferro; Jordi Bruix; Erwin Bottinger; Scott Friedman; Samuel Waxman; Josep M Llovet
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

4.  VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-κB and β-catenin.

Authors:  Minna Luo; Lei Hou; Jian Li; Shan Shao; Shangke Huang; Du Meng; Lifeng Liu; Lu Feng; Peng Xia; Tianjie Qin; Xinhan Zhao
Journal:  Cancer Lett       Date:  2016-01-19       Impact factor: 8.679

5.  Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.

Authors:  Cécile Guichard; Giuliana Amaddeo; Sandrine Imbeaud; Yannick Ladeiro; Laura Pelletier; Ichrafe Ben Maad; Julien Calderaro; Paulette Bioulac-Sage; Mélanie Letexier; Françoise Degos; Bruno Clément; Charles Balabaud; Eric Chevet; Alexis Laurent; Gabrielle Couchy; Eric Letouzé; Fabien Calvo; Jessica Zucman-Rossi
Journal:  Nat Genet       Date:  2012-05-06       Impact factor: 38.330

6.  Negatively charged AuNP modified with monoclonal antibody against novel tumor antigen FAT1 for tumor targeting.

Authors:  Li Fan; Susanna Campagnoli; Hong Wu; Alberto Grandi; Matteo Parri; Elisa De Camilli; Guido Grandi; Giuseppe Viale; Piero Pileri; Renata Grifantini; Chaojun Song; Boquan Jin
Journal:  J Exp Clin Cancer Res       Date:  2015-09-15

7.  Regulation of the inflammatory profile of stromal cells in human breast cancer: prominent roles for TNF-α and the NF-κB pathway.

Authors:  Christina Katanov; Shalom Lerrer; Yulia Liubomirski; Leonor Leider-Trejo; Tsipi Meshel; Jair Bar; Rotem Feniger-Barish; Iris Kamer; Gali Soria-Artzi; Hadar Kahani; Debabrata Banerjee; Adit Ben-Baruch
Journal:  Stem Cell Res Ther       Date:  2015-05-01       Impact factor: 6.832

8.  miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1.

Authors:  Yonglei Liu; Yutong Wang; Xiangjun Sun; Chuanzhong Mei; Liying Wang; Zengxia Li; Xiliang Zha
Journal:  Oncotarget       Date:  2016-03-22

9.  Berberine Targets AP-2/hTERT, NF-κB/COX-2, HIF-1α/VEGF and Cytochrome-c/Caspase Signaling to Suppress Human Cancer Cell Growth.

Authors:  Lingyi Fu; Wangbing Chen; Wei Guo; Jingshu Wang; Yun Tian; Dingbo Shi; Xiaohong Zhang; Huijuan Qiu; Xiangsheng Xiao; Tiebang Kang; Wenlin Huang; Shusen Wang; Wuguo Deng
Journal:  PLoS One       Date:  2013-07-15       Impact factor: 3.240

10.  POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.

Authors:  Daniel J Sharpe; Katy S Orr; Michael Moran; Sharon J White; Stephen McQuaid; Terence R Lappin; Alexander Thompson; Jacqueline A James
Journal:  Oncotarget       Date:  2014-09-30
View more
  12 in total

1.  Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.

Authors:  Yizhen Fu; Zhenyun Yang; Zili Hu; Zhoutian Yang; Yangxun Pan; Jinbin Chen; Juncheng Wang; Dandan Hu; Zhongguo Zhou; Li Xu; Minshan Chen; Yaojun Zhang
Journal:  Hepatol Int       Date:  2022-06-08       Impact factor: 9.029

2.  LncRNA LINC01116 Promotes the Development of Colorectal Cancer by Targeting miR-9-5p/STMN1.

Authors:  Chongyao Bi; Hongshuai Cui; Haijing Fan; Lai Li
Journal:  Onco Targets Ther       Date:  2020-10-15       Impact factor: 4.147

3.  Characterization of POU2F1 Gene and Its Potential Impact on the Expression of Genes Involved in Fur Color Formation in Rex Rabbit.

Authors:  Naisu Yang; Bohao Zhao; Shuaishuai Hu; Zhiyuan Bao; Ming Liu; Yang Chen; Xinsheng Wu
Journal:  Genes (Basel)       Date:  2020-05-20       Impact factor: 4.096

4.  Prognostic potential of PRPF3 in hepatocellular carcinoma.

Authors:  Yinlan Liu; Yuhan Yang; Yan Luo; Juan Wang; Xiangyun Lu; Zongxing Yang; Jin Yang
Journal:  Aging (Albany NY)       Date:  2020-01-11       Impact factor: 5.682

5.  Gene networks and transcriptional regulators associated with liver cancer development and progression.

Authors:  Tatiana Meier; Max Timm; Matteo Montani; Ludwig Wilkens
Journal:  BMC Med Genomics       Date:  2021-02-04       Impact factor: 3.063

6.  The Synergistic Antitumor Effect of Tanshinone IIA Plus Adriamycin on Human Hepatocellular Carcinoma Xenograft in BALB/C Nude Mice and Their Influences on Cytochrome P450 CYP3A4 In Vivo.

Authors:  Tao-Li Liu; Li-Na Zhang; Yue-Yu Gu; Mei-Gui Lin; Jun Xie; Yu-Ling Chen; Jia-Hui Liu; Xin-Lin Wu; Sui-Lin Mo
Journal:  Adv Med       Date:  2020-02-29

7.  POU2F1 Promotes Cell Viability and Tumor Growth in Gastric Cancer through Transcriptional Activation of lncRNA TTC3-AS1.

Authors:  Jixu Wang; Ke Xiao; Futao Hou; Lusheng Tang; Dan Luo; Gu Liu; Zhiqiang Wang
Journal:  J Oncol       Date:  2021-06-28       Impact factor: 4.375

8.  Oct1/Pou2f1 is selectively required for colon regeneration and regulates colon malignancy.

Authors:  Karina Vázquez-Arreguín; Claire Bensard; John C Schell; Eric Swanson; Xinjian Chen; Jared Rutter; Dean Tantin
Journal:  PLoS Genet       Date:  2019-05-06       Impact factor: 5.917

9.  Targeting FAT1 Inhibits Carcinogenesis, Induces Oxidative Stress and Enhances Cisplatin Sensitivity through Deregulation of LRP5/WNT2/GSS Signaling Axis in Oral Squamous Cell Carcinoma.

Authors:  Tung-Nien Hsu; Chih-Ming Huang; Chin-Sheng Huang; Mao-Suan Huang; Chi-Tai Yeh; Tsu-Yi Chao; Oluwaseun Adebayo Bamodu
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

10.  The POU2F1/miR-4490/USP22 axis regulates cell proliferation and metastasis in gastric cancer.

Authors:  Yizhi Xiao; Side Liu; Jiaying Li; Weiyu Dai; Weimei Tang; Li Xiang; Wenjing Zhang; Jianjiao Lin; Jing Wang; Xiaosheng Wu; Guangnan Liu; Yuyang Liu; Yaying Chen; Huiqiong Zhu; Yusi Wang; Zhizhao Lin; Qiong Yang; Tianming Chen; Yong Sun; Aimin Li; Jing Xiong; Jide Wang
Journal:  Cell Oncol (Dordr)       Date:  2020-08-28       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.